Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Solassol

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Pharmaceutical and Biomedical Analysis|November 2, 2013
Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometryFlorian Lafaille, Isabelle Solassol, Christine Enjalbal, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 27, 2009
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanomaSonia Khier, Carine Deleuze-Masquéfa, Georges Moarbess, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2010
Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomasSonia Khier, Florence Gattacceca, Safia El Messaoudi, et al.
International Journal of Molecular Sciences|September 28, 2023
Differential Sensitivity of Germline and Somatic <i>BRCA</i> Variants to PARP Inhibitor in High-Grade Serous Ovarian CancerJulie A Vendrell, Iulian O Ban, Isabelle Solassol, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Pharmaceutical and Biomedical Analysis|November 2, 2013
Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometryFlorian Lafaille, Isabelle Solassol, Christine Enjalbal, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 27, 2009
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanomaSonia Khier, Carine Deleuze-Masquéfa, Georges Moarbess, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2010
Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomasSonia Khier, Florence Gattacceca, Safia El Messaoudi, et al.
International Journal of Molecular Sciences|September 28, 2023
Differential Sensitivity of Germline and Somatic <i>BRCA</i> Variants to PARP Inhibitor in High-Grade Serous Ovarian CancerJulie A Vendrell, Iulian O Ban, Isabelle Solassol, et al.
Pageof 2